Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo - PubMed (original) (raw)
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo
Jung-Guk Kim et al. Diabetes. 2003 Mar.
Abstract
The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl peptidase-IV (DPP-IV) has fostered new approaches for generation of degradation-resistant GLP-1 analogues. We examined the biological activity of CJC-1131, a DPP-IV-resistant drug affinity complex (DAC) GLP-1 compound that conjugates to albumin in vivo. The CJC-1131 albumin conjugate bound to the GLP-1 receptor (GLP-1R) and activated cAMP formation in heterologous fibroblasts expressing a GLP-1R. CJC-1131 lowered glucose in wild-type mice, but not in GLP-1R-/- mice. Basal glucose and glycemic excursion following glucose challenge remained significantly reduced 10-12 h following a single injection of CJC-1131. Twice daily administration of CJC-1131 to db/db mice significantly reduced glycemic excursion following oral and IP glucose challenge (P < 0.01 to 0.05) but did not significantly lower body weight during the 4-week study period. Levels of random fed glucose were significantly lower in CJC-1131-treated +/+ and db/db mice and remained significantly lower even 1 week following discontinuation of CJC-1131 administration. CJC-1131 increased levels of pancreatic proinsulin mRNA transcripts, percent islet area, and the number of bromodeoxyuridine-positive islet cells. These findings demonstrate that an albumin-conjugated DAC:GLP-1 mimics the action of native GLP-1 and represents a new approach for prolonged activation of GLP-1R signaling.
Similar articles
- Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP. Green BD, et al. Biol Chem. 2003 Dec;384(12):1543-51. doi: 10.1515/BC.2003.171. Biol Chem. 2003. PMID: 14719796 - An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL, Huang Q, Cao X, Drucker DJ. Baggio LL, et al. Gastroenterology. 2008 Apr;134(4):1137-47. doi: 10.1053/j.gastro.2008.01.017. Epub 2008 Jan 11. Gastroenterology. 2008. PMID: 18313669 - Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review. - Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR. O'Harte FP, et al. Regul Pept. 2001 Jan 12;96(3):95-104. doi: 10.1016/s0167-0115(00)00125-7. Regul Pept. 2001. PMID: 11111014 - Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ. Drucker DJ. Curr Pharm Des. 2001 Sep;7(14):1399-412. doi: 10.2174/1381612013397401. Curr Pharm Des. 2001. PMID: 11472275 Review.
Cited by
- Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.
Bernardim B, Conde J, Hakala T, Becher JB, Canzano M, Vasco AV, Knowles TPJ, Cameron J, Bernardes GJL. Bernardim B, et al. Bioconjug Chem. 2024 Feb 21;35(2):132-139. doi: 10.1021/acs.bioconjchem.3c00478. Epub 2024 Feb 12. Bioconjug Chem. 2024. PMID: 38345213 Free PMC article. - Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A, Heck A, Ruiz-Blanco YB, Gilg A, Ständker L, Kuan SL, Weil T, Sanchez-Garcia E, Wiese S, Münch J, Harms M. Rodríguez-Alfonso A, et al. Int J Mol Sci. 2022 Nov 30;23(23):15029. doi: 10.3390/ijms232315029. Int J Mol Sci. 2022. PMID: 36499357 Free PMC article. - An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.
Lu W, Tian H, Qian P, Li Y, Wang Y, Ge Y, Sai W, Gao X, Yao W. Lu W, et al. Br J Pharmacol. 2020 Aug;177(15):3473-3488. doi: 10.1111/bph.15069. Epub 2020 Jun 7. Br J Pharmacol. 2020. PMID: 32293707 Free PMC article. - Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.
McBrayer DN, Tal-Gan Y. McBrayer DN, et al. Drug Dev Res. 2017 Sep;78(6):292-299. doi: 10.1002/ddr.21404. Epub 2017 Aug 8. Drug Dev Res. 2017. PMID: 28786125 Free PMC article. Review. - Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.
Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, Brown AJ, Zhou C, Deng J, Wang MW. Graaf Cd, et al. Pharmacol Rev. 2016 Oct;68(4):954-1013. doi: 10.1124/pr.115.011395. Pharmacol Rev. 2016. PMID: 27630114 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous